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Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic
kidney disease in the Han:SPRD rat. Thickening of the tubular basement
membrane is one of the hallmarks of polycystic kidney disease (PKD). The
present study was conducted to investigate the potential role of the matrix
metalloproteinase-2 (MMP-2) and its specific tissue inhibitors (TIMP-1
and TIMP-2) in the accumulation of matrix components in PKD. As a
model of PKD, two-month-old heterozygous Han:SPRD rats, which are at
an early stage of cystogenesis, were used. MMP-2, but not MMP-9
(gelatinase B) nor MMP-3 (stromelysin) could be detected in proximal
tubules of the normal rat kidney. The presence of the inhibitors TIMP-l
and TIMP-2 was confirmed on the mRNA level. In tubules from PKD rats
MMP-2 activity was lower (31 8 vs. 58 7 U/prep., N = 9, P < 0.05),
mRNA of MMP-2 was reduced 4.2 0.6-fold (N = 4, P < 0.05) and
enzyme protein was depressed 3.8 0.8-fold (N = 4, P < 0.05). By
contrast, TTMP-1 mRNA was 9.0 1.1-fold and TIMP-2 mRNA 3.8
0.7-fold (N = 4, P < 0.05) elevated over controls. Cyst fluid from
homozygous rats contained MMP-2 protein and activity. These findings
indicate that tubular MMP-2 activity is reduced in PKD, due to down-
regulation of MMP-2, up-regulation of TIMP-1 and TIMP-2, and luminal
secretion of the enzyme. It is conceivable that these alterations relate to
the enhanced matrix accumulation observed in the evolution of PKD.
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common hereditary disorders in humans, which
is estimated to afflict 1 in 1000 live births. This disease accounts
for up to 10% of all cases of end-stage renal disease [1]. The
phenotypic expression of ADPKD is characterized by innumera-
ble cysts scattered throughout the cortex and medulla of both
kidneys. The cysts progressively enlarge and lead to the onset of
chronic renal failure by the sixth decade in approximately one-half
of the affected individuals [2]. Three major pathophysiological
events have been identified to explain cyst formation: enhanced
proliferation of tubular epithelia, transepithelial secretion of fluid
into the cyst and abnormal turnover of tubulointerstitial matrix
[3—6].
The turnover of extracellular matrix is dependent on a balance
between its synthesis and degradation, and consequently en-
hanced matrix deposition may be either due to increased synthesis
and/or reduced activity of proteinases responsible for the remod-
eling of the matrix components. Several lines of evidence suggest
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the involvement of metalloproteinases (MMPs) in matrix turn-
over, including the glomerular extracellular matrix [7—111. The
gene family of MMPs includes the collagenases, gelatinases and
stromelysins, which are Zn-dependent endopeptidases with the
combined ability to degrade all the components of ECM at
physiological pH [12—14]. These enzymes are specifically inhibited
by tissue inhibitors of metalloproteinases (TIMPs), of which
TIMP-1, TIMP-2 and TIMP-3 have been described [15—18].
Several studies have highlighted the putative role of MMPs and
their specific inhibitors (TIMPs) in the degradation of extracellu-
lar matrix including the matrix of the glomerulus [8, 9]. By
contrast, little is known concerning tubular metalloproteinases.
Walker, Kaushal and Shah [19] described a laminin-degrading
activity in rat renal tubular homogenates, which could be inhibited
by EDTA but not by TIMP. In a later paper the authors identified
this metalloproteinase as meprin, which had been shown previ-
ously to degrade azocasein and the insulin B chain, but was not
known to cleave extracellular matrix components [20]. MMP-2
and MMP-9 were identified by zymography in conditioned media
from cultured rat and mouse tubular epithelial cells [21, 22] as
well as from cystic cpk/cpk mouse cells [23].
The objective of the present study was twofold: (1) to define
MMPs and TIMPs from normal proximal tubules; and (2) to
investigate whether the levels of these proteinases and their
inhibitors were altered in a model of heterozygous PKD rats
(Han:SPRD) in an early stage of cystogenesis.
Methods
Animals
Homozygously (cy/cy) and heterozygously (cy/+) affected male
Han:SPRD rats as well as healthy littermates (+/+) were used in
this study. This model of ADPKD is derived from a spontaneous
mutation in the Sprague-Dawley strain and the disease is trans-
mitted in an autosomal dominant pattern. Homozygous animals
develop excessive cysts with gross renal enlargement and die early
(after 4 weeks) from renal failure. By contrast, heterozygously
afflicted rats suffer from slow, progressive renal cystic disease and
death usually occurs after 12 to 21 months [24—26].
Heterozygously affected Han:SPRD rats (cy/+) were investi-
gated at the age of two months. Age-matched, unaffected litter-
mates (+/+) were used as control animals. The presence of
enlarged kidneys was checked by abdominal palpation and further
controlled by histopathology to identify affected animals. Cyst
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fluid was obtained from homozygous three-week old Han:SPRD
rats. All animal experiments were conducted in accord with the
NIH Guide for the Care and Use of Laboratory Animals.
Isolation and characterization of proximal tubules
Animals were anesthetized with hexobarbital (150 mg/kg), the
kidneys removed, and tubules isolated according to the method of
Spiro [271. In brief, renal cortex from one kidney of each animal
was minced and resuspended in ice-cold saline. A sample of the
total homogenate was reserved and the rest of the homogenate
was passed through a stainless steel sieve (250 m pore size,
Linker, Kassel, Germany). The sieved material was suspended in
ice-cold saline and poured over a 50 jim nylon sieve (Schweiz-
erische Seidengazefabrik, Zurich, Switzerland), thereby allowing
cell debris and small fragments to pass through, while retaining
glomeruli and tubules. Separation of tubules from glomeruli was
achieved by passage on a 150 jim nylon sieve. The tubuli which
were retained by this sieve were resuspended on 50% Percoll and
centrifuged at 12,200 g for 30 minutes at 4°C according to Vinay,
Gougoux and Lemieux [28]. This preparation contained proximal
tubules obtained from a single kidney after sieving and Percoll
gradient separation.
The fraction containing proximal tubules was resuspended in
0.9% saline, washed three times and then examined by light
microscopy. A sample from each preparation was also processed
for histological evaluation after formalin fixation and periodic
acid-Schiff (PAS) staining. This allows for clear differentiation
between proximal (granular yellow cytoplasm and pink brush
border membrane) and distal tubular epithelia (clear cytoplasma,
no brush border membrane) [28]. The purity of the proximal
tubular preparation was 95%. Isolated proximal tubules were
either used for RNA isolation or were disrupted by sonication (5
bursts, 2 seconds each) at 4°C for the measurements of enzyme
activities.
Cyst fluid samples
Cyst fluids from homozygous polycystic kidneys were obtained
by puncture and were free of leukocytes. Proteolytic enzyme
activities were measured in unconcentrated supernatants after
centrifugation and filtration through a 0.2 jim Durapore mem-
brane which consists of polyvinylidenfluoride and displays very
low protein binding (Millipore, Eschborn, Germany). Prior to
zymography cyst fluids were concentrated 10 times using mi-
croconcentrators (Microcon 10, Amicon, Beverly, MA, USA).
Gelatinolytic activity
Gelatinolytic enzyme activities were measured fluorometrically
as described by us previously [29]. Denatured (gelatin) rat tail
collagen type-I was used as substrate. Latent enzyme was acti-
vated by preincubation with 0.5 m of oxidized glutathione. The
activity of gelatinase was determined in the presence of 4 m
PMSF for inhibition of serine proteinases. After 18 hours of
incubation at 25°C, the digested fragments were labeled with 2%
fluorescamine. Fluorescence was measured by excitation at 390
nm and emission at 475 nm. The assay was quantified by deter-
mening a calibration curve relating the fluorescence emission
reading to an equivalent concentration of H-Leu-Leu-OH
(Bachem, Heidelberg, Germany). One unit was defined as 1.0 flM
amino groups cleaved from the gelatin molecule per minute.
Zymograms
SDS substrate gels were prepared by including gelatin or casein
at a final concentration of I mg/mi in standard 10% acrylamide
gels according to Laemmli [301. Electrophoresis was performed
under non-reducing conditions at 4°C and 20 mAlgel. Thereafter,
gels were washed for one hour at room temperature in 2.5%
vol/vol Triton X-100 with two changes, and then incubated over
night at 37°C in 50 mrvi Tris-HCI/0.1 M NaC1/10 mi CaCl2/4 mM
PMSF/0.05% Brij/pH 7.6 in the presence or absence of 20 mM
EDTA. Staining was achieved with Coomassie Blue R-250. A
high-molecular mixture of protein (205 to 29 kD; Sigma, Munich,
Germany) was used as molecular standards.
Western blot analysis
Prior to electrophoresis homogenates of proximal tubules con-
taining equal amounts of protein or samples of cyst fluid were
activated with 2 mrvi APMA (4-aminophenolmercuric acetate)
(Sigma) for 18 hours at 25°C and applied to a gelatin-Sepharose
column (1 ml) equilibrated in 10 mrvi Tris/HC1 pH 7.6/5 mrvi
CaCl2/0.04% Brij 35 (vol/vol) and washed with the same buffer.
Bound material was eluted with equal volume of the same buffer
plus 10% DMSO. The gelatin-binding fraction was further con-
centrated 50-fold using Microcon 10 concentrators. Samples (20
gil) and standard purified human MMPs (100 ng) were subjected
to electrophoresis on 10% (wt/vol) gels under reducing condi-
tions. Proteins were transferred electrophoretically at 100 V for
one hour to nitrocellulose membranes using the Bio-Rad Mini
Trans-Blot Apparatus as recommended by the manufacturer. The
membranes were blocked by incubation with 1% (wt/vol) BSA in
PBS containing 0.1% (vol/vol) Tween 20 (PBST) for two hours.
After washing in PBST for five minutes, the nitrocellulose was
incubated over night at 4°C with the primary antibody in a dilution
of 1:500 (rabbit polyclonal antibody to human MMP-2; Anawa,
Zurich, Switzerland) in PBS containing 0.05% Tween 20 and 1%
BSA (PBSTB). Thereafter, the nitrocellulose strips were washed
for one hour in PBST and incubated in PBSTB containing the
second antibody in a dilution of 1:1000 (anti-rabbit IgG, peroxi-
dase-linked, species specific whole antibody) from Amersham
(Amersham, UK) for one hour. The strips were then extensively
washed in PBST and incubated in ECL Western blotting detection
reagent (Amersham) and exposed to Kodak X-OMAT AR film.
Northern blot analysis
Northern blots were performed on total RNA extracted from
proximal tubules isolated from single animals with the acid
guanidinium thiocyanate phenol chloroform extraction method
[31]. Total RNAwas quantitated by UV spectrophotometry at 260
nm and 280 nm. RNA samples (20 to 40 jig per lane) were
denatured and electrophoresed through 1.2% agarose formalde-
hyde gels and then transferred by pressure blotter (Posi Blot,
Stratagene, La Jolla, CA, USA) onto nylon filters (GeneScreen,
DuPont-NEN, Boston, MA, USA). The RNA was fixed to the
filters by ultraviolet irradiation for two minutes at 254 nm (UV
Stratalinker, Stratagene).
All probes were radiolabeled with [32P]dCTP (3,000 Ci/mmol)
using random decamer oligonucleotide primers and Kienow en-
zyme [32] with the DECAprime DNA labeling kit (Ambion,
Austin, TX, USA). Membranes were prehybridized at least for
two hours at 42°C in 5 X SSPE/50% deionized formamide/5X
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Table 1. Body weights, single kidney weights and renal function in





Body weight g 331 6 334 9
Kidney weight g 2.1 0.12° 1.1 0.05
Serum creatinine mg/dl 0.61 0.03 0.54 0.02
Creatinine clearance p.J/min/100 g 472 25 491 24
Data are given as means SEM from 9 animals in each group.
aP < 0.05 for heterozygous PKD vs. healthy offspring (2 months)
Denhard's/0.5% SDSI5O tg/ml herring sperm DNA. Hybridiza-
tion was carried out overnight at 42°C. The filters were washed
twice for 15 minutes in 2 X SSPE at room temperature and then
agitated in 2 x SSPE/2% SDS at 65°C for 30 minutes and exposed
to Kodak X-OMAT AR film at —80°C for one to four days. After
autoradiography, the filters were stripped and hybridized accord-
ing to the same procedure with a human GAPDH cDNA probe
(1.2 kb Pstl restriction fragment of pBR 322). A 0.24 to 9.5 kb
RNA ladder (Gibco BRL, Gaithersburg, MD, USA) was used as
reference for RNA size. The autoradiographs were digitized using
an EPSON GT 6000 scanner (Epson, Tokyo, Japan). For all RNA
samples the density of each individual RNA band was normalized
for that of a GAPDH mRNA band to correct for the difference in
RNA loading and/or transfer. Data were expressed in relative
optical density units.
Plasmids containing eDNA for mouse MMP-2 (pBR 322),
MMP-9 (pBluescript II SK) were kindly provided by Dr. K.
Tryggvason (University of Oulu, Finland) and cDNAs for mouse
TIMP-1 and TIMP-2 (pBS) were a gift from Dr. K. Leco (University
of Calgary, Canada). The plasmid containing eDNA for rat
MMP-3 (pUN 121) was obtained from ATCC (Rockville, MD,
USA).
Restriction fragments isolated from these plasmids were as
follows: EcoRl 2.8 kb fragment for MMP-2; EcoRI 1.7 kb
fragment for MMP-3; EcoRI-HindIII 1.8 kb fragment for MMP-9;
BamHI/HindIII 825 bp fragment for TIMP-1; and HindIII/XhoI
700 bp fragment for TIMP-2.
Analytical methods
Each preparartion of isolated tubules and samples of total
cortical homogenates were assayed for fructose-1,6-diphosphatase
activity according to the method of Pontremoli et al [33]. Results
were expressed as U (nM of substrate converted per mm at 37°C)
per whole kidney cortex. Analysis of serum and urine samples for
creatinine was performed using a Technicon autoanalyzer (Bayer
Diagnostics, Munich, Germany).
Statistics
Results were expressed as means SEM, Statistical analysis was
performed using the unpaired Student's f-test. Significance was
accepted at the 5% level.
Results
Kidney weight and function in hetero2ygous PKD rats
The body wt was comparable in two-month-old polycystic (331
6 g) and control animals (334 9 g). Kidney weight was
considerably higher in PKD rats (2.1 0.1 g) than in control
Table 2. Gelatinolytic activities in proximal tubules from heterozygous








PKD 3.0 0.7 31.2 8.3° 1.2 0.3
Controls 5.6 0.9 57.9 6.9 2.4 0.4
Data are given as means SEM from 9 animals in each group. All
experiments were performed in the presence of 4 mvt PMSF.
aP < 0.05 for PKD animals vs. healthy offspring (2 months)
animals (1.1 0.05 g) and the enlarged kidneys could be readily
detected by abdominal palpation. Polycystic animals displayed
normal glomerular filtration rates, as measured by creatinine
clearance, Clinically these rats appeared healthy and showed no
signs and symptoms of uremia (Table 1).
Characterization of isolated proximal tubules
Light microscopy of PAS-stained preparations revealed that
proximal tubules were isolated to a purity of 95% and no
glomeruli were detectable. To demonstrate that the isolation
procedure resulted in comparable preparations from both PKD
and control animals, the activity of fructose-1,6-diphosphatase, a
specific marker for proximal tubular epithelial cells [25], was
measured both in the kidney cortex homogenate and in the final
proximal tubule preparation. Enzyme activity in the cortical
homogenate was comparable in PKD and control rats (PKD 294.4
23.8 vs. controls 301.6 21.7 U/kidney cortex; N = 9). In
parallel, isolated tubules from the initial homogenate also dis-
played more or less identical fructose-1,6-diphosphate activities
(PKD 226.1 22.4 vs. controls 234.9 18.9 U/tubular prep.; N =
9). This represents a 77.7% and 76.8% recovery, respectively, and
indicates that the isolation resulted in comparable tubular prep-
arations both from normal and diseased kidneys. Furthermore,
the amount of protein in both preparations was comparable (PKD
5.7 0.8 vs. 6.2 0.6 mg per tubular preparation; N = 9).
Tubular gelatinolytic activities
Gelatinolytic activities found in proximal tubules from control
and PKD animals were mainly due to latent forms of enzymes,
since measurements without activation by oxidized glutathione
resulted in activities of less than 10% of total gelatinolytic activity
in proximal tubules of both control and PKD animals (Table 2).
The results also show that tubules prepared from PKD rats
contained significantly lower gelatinolytic activities (PKD 31.2
8.3 vs. Controls 57.9 6.9 U/tubular preparation; N = 9, P <
0.05). These assays were performed in the presence of the serine
proteinase inhibitor PMSF (4 mM). When EDTA was added, it
resulted in a more than 95% enzyme inhibition, indicating that
these activities were indeed due to metalloproteinases (Table 2).
To further define this gelatinolytic activity samples were sub-
jected to gelatin and casein zymography. With gelatin as a
substrate, bands of enzyme activity were readily identified at 72
kD, 68 kD and a 62 kD from both healthy and PKD rats (Fig. 1,
lanes A, B). This suggests that the activity was due to the
proenzyme and two active forms of gelatinase A. These bands
were not obtained if EDTA was added. Furthermore and in
agreement with the fluorometric analysis, proximal tubules from
PKD animals displayed lower intensity bands than those from
Fig. 1. Zymogram (lanes A and B) and Western
blot analysis (lanes C and D) of gelatinase A
(MMP-2) in proximal tubules isolated from PKD
and control rats. Tubular MMP-2, yielding a
triplet of gelatinolytic activity (72, 68 and 62
kD), which was reduced in PKD (lane A) as
compared to healthy rats (lane B). MMP-2
protein from PKD (lane C) and healthy animals
(lane D) were recognized by Western blotting
(68 and 62 kD bands) using a polyclonal
antibody to human MMP-2. Enzyme protein,
measured by densitometry, was 3.8-fold lower
(N = 4; P < 0.05) in tubular preparations of
PKD animals.
controls (Fig. 1, lane A vs. B). This semiquantitative estimation
became possible because equal volumes of the final tubular
preparation from PKD and control animals were subjected to
electrophoresis. No other bands at 92 kD were detected. For the
detection of stromelysin casein zymography was performed, but
did not reveal any activity bands in tubular preparations from both
healthy or PKD rats.
Western blotting of tubular MMP-2
For further characterization of the gelatinolytic activity, West-
ern blot analysis was conducted using a polyclonal antibody
against human MMP-2, which cross reacts with the rat protein [91.
The antiserum recognized protein bands of 68 and 62 kD, which
exactly corresponded with the activity bands detected by zymog-
raphy (Fig. 1 lanes C, D). Under the conditions of the experiment
the protein bands of MMP-2 in tubular preparations from PKD
animals were markedly less in comparison to control animals (Fig.
1, lanes C vs. D). Densitometric evaluation showed that tubular
MMP-2 protein from PKD was 3.8 0.8-fold (N = 4; P < 0.05)
lower as compared to tubular control samples.
Tubular mRNA expression of MMP-2 and TIMPs
Northern blot analysis of MMP-2 mRNA expression in proxi-
mal tubules from PKD animals was also performed. As can be
seen in Figure 2 there was down-regulation of the MMP-2 gene in
tubules from PKD rats as compared to controls. In contrast, a
different expression pattern for both tissue inhibitors of metallo-
proteinases (TIMP-1 and TIMP-2) was observed. In comparison
to healthy controls, TIMP-1 (Fig. 3) and TIMP-2 (Fig. 4) mRNA
expression in proximal tubules was up-regulated in PKD rats.
Densitometric analysis of MMP-2 mRNA showed that these
signals were 4.2 0.6-fold lower (N = 4; P < 0.05) in proximal
tubules from PKD rats. On the other hand, the contents of mRNA
for TIMP-i and TIMP-2 were considerably increased (9.0
1.1-fold [N = 4; P < 0.05] and 3.8 0.7-fold [N = 4; P < 0.05],
respectively) in proximal tubules from PKD as compared to
control rats. Regarding MMP-3, no mRNA was detectable by
Northern blot analysis.
MMP-2 in cyst fluid
Cyst fluid from homozygous PKD rats showed gelatinolytic
activity of 735 127 mU/mi after activation by glutathione, while
in the absence of glutathione the activity was only 51.5 9.8
mU/ml, indicating that 93% of the enzyme was present in the
latent form. These activities was determined after preincubation
with 4 mvt PMSF and 1 mi E-64 in order to inhibit serine and
cysteine proteinases, respectively. In the presence of EDTA the
total enzyme activity declined to 4.1 0.5 mU/ml. Gelatin
zymography of cyst fluid samples showed bands at 72, 68 and 62
kD (Fig. 5, lane A). Incubation with 20 mrvi EDTA completely
PKD Control PKD Control
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Fig. 2. Northern blot analysis of tubular MMP-2 mRNA of PKD and control
rats. As measured by densitometry, the levels of mRNA coding for MMP-2
were 4.2 0.6-fold lower in PKD (N = 4; P < 0.05) as compared to
healthy controls. Expression of GAPDH mRNA in the same membrane is
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Fig. 3. Northern blot analysis of tubular TIMP-] mRNA of PKD and control
rats. The levels of mRNA coding for TIMP-1, measured by densitometiy,
were 9.0 1.1-fold higher in PKD (N = 4; P < 0.05) as compared to
control animals. Expression of GAPDH mRNA in the same membrane is
shown on the lower panel.
Fig. 5. Zymography of cyst fluid MMP-2, yielding a triplet of gelatinolytic
activity (72, 68 and 62 kD; lane A). In the presence of 20 mivi EDTA
MMP-2 is completely inhibited (lane B). Using a polyclonal antibody to
human MMP-2, Western blotting revealed a 68 kD and 62 kD form of cyst
fluid MMP-2 (lane C).
casein zymography, but no activity bands of MMP-3 were de-
tected.
Discussion
Fig. 4. Northern blot analysis of tubular TIMP-2 mRNA of PKD and control
rats. The levels of mRNA coding for TIMP-2, measured by densitometry,
were 3.8 it 0.7-fold higher in PKD (N = 4; P < 0.05) as compared to
control animals. Expression of GAPDH mRNA in the same membrane is
shown on the lower panel.
inhibited these activities (Fig. 5, lane B). Western blotting with a
polyclonal antibody against MMP-2 recognized the 68 and 62 kD
protein bands (Fig. 5, lane C), confirming that these activities
were due to MMP-2. No other bands at 92 kD were detected in
the cyst fluid by zymography. Samples were also subjected to
Our findings provide evidence for the presence of a 72 kD
gelatinase (MMP-2) as well as TIMP-1 and TIMP-2 in proximal
tubules from normal rat kidneys. In contrast, we were unable to
detect 92 kD gelatinase (MMP-9) and stromelysin (MMP-3) in
the same preparations. In comparison to controls, tubular prepa-
rations from PKD animals displayed significantly reduced gelati-
nolytic activity. The likely reason for this was probably a down-
regulation of tubular MMP-2 and an up-regulation of TIMP-l and
TIMP-2, which we demonstrated in terms of gene expression. As
cyst fluid contained MMP-2 activity and protein, aberrant secre-
tion of the enzyme into the luminal space might have also
contributed to the reduced gelatinase activity in tubular prepara-
tions from PKD animals.
Physiologically matrix metalloproteinases are secreted into the
extracellular space [13], and many investigators have measured
these enzymes in culture supernatants from various renal cells [10,
Il, 34, 35]. In the present study, however, we were able to
demonstrate both MMP-2 activity and protein within isolated
proximal tubules. These findings are in agreement with the
immunohistochemistry data from Norman et al [36] who showed
that proximal human tubules were stained positively for MMP-2.
It is of note that MMP-2 is unique among all other MMPs in
that it cannot be activated by proteinases such as kallikrein,
neutrophil elastase or cathepsin G [37], which have been identi-
fled as putative activators of the MMP family. Instead pro-MMP-2
appears to be activated after secretion by binding to an as yet
unidentified pro-MMP-2-receptor on the cell surface, and then
proteolytically cleaved to the active enzyme by a membrane-type
MMP [38]. Thus, binding of MMP-2 to the cell surface, which has
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MMP-2 activity in the tubular preparation which is free of
interstitial matrix.
In general, there are only a few reports that address the
potential involvement of tubular metalloproteinases in the evolu-
tion of PKD. In advanced stages of human ADPKD Norman et al
[361 observed reduced MMP-2, MMP-3 and MMP-9 proteins as
determined by immunohistochemistry, while the expression of
TIMP protein was simultaneously increased. This fits quite well to
our findings in isolated tubules from the heterozygous Han:SPRD
rat, which displayed reduced MMP-2 mRNA, protein and activity,
while mRNAs for TIMP-1 and TIMP-2 were markedly overex-
pressed.
In addition, a number of preliminary reports has also addressed
MMP-2 in conditioned media of cultured tubular epithelia from
the cpk mouse, a model of the autosomal recessive form of PKD.
While Norman et al [22] observed lower MMP-2 activity (deter-
mined by zymography), van Adelsberg [40] reported that cystic
and normal tubular cells from cpklcpk mice secreted the same
amount of MMP-2 protein, and Rankin et al [23] found increased
activities of MMP-2 by zymography. These preliminary in vitro
data are difficult to interpret and some of the differences are most
likely due to different culture conditions and cell lines. Van
Adelsberg [41] used immortalized cells, while Norman et al [22]
and Rankin et al [23] used primary tubular cell cultures from the
cpk mouse.
In terms of MMP-2 and TIMP, our in vivo findings in the
heterozygous Han:SPRD rat correspond quite well with the
observations of Norman et al both in human ADPK [36] as well as
in the cpk mouse model [22]. However, with respect to MMP-3
(stromelysin) we found neither enzyme activity by casein zymog-
raphy, nor did we demonstrate mRNA for this enzyme both in
tubules from normal and PKD animals. This contrasts with
findings in human ADPKD, where Norman et al [36] and
Gardener et al [42] demonstrated MMP-3 protein to be present
either in tubular epithelia or in the cyst fluid. We are well aware
that the casein zymography is less sensitive than the zymography
using gelatin for the detetcion of MMP-2 and MMP-9. Similarily,
Northern blot analysis of total RNA may not detect very small
amounts of MMP-3 mRNA. Thus, we cannot rule out that minute
amounts of MMP-3 mRNA were present which might would have
been detected by amplification using RT-PCR techniques.
In contrast to Norman et al [22, 36J who found MMP-9 in cyst
epithelia from human and cpk mouse kidneys, we could not detect
this enzyme in proximal tubules from the Han:SPRD rat. We do
not think that this was due to technical problems, because we
readily detected MMP-9 mRNA in isolated glomeruli from the
same kidneys (data not shown).
These obvious discrepancies may be due to the fact that MMP-2
and MMP-9 are independently regulated, with the MMP-2 gene
possessing an AP2 promotor site [43], while transcription of the
MMP-9 gene is being controlled through the gene promotor
sequence APi [44]. In many tissues MMP-2 is expressed consti-
tutively and is linked to the normal turnover of the extracellular
matrix, while MMP-9 is only expressed upon stimulation with
cytokines such as interleukin-1 through the API promotor site
[101. Therefore, it may be conceivable that we could not demon-
strate tubular MMP-9 at an early stage of renal cyst formation,
while others have found this enzyme at more advanced stages of
PKD or under cell culture conditions, where changes in the
expression of metalloproteinases have been reported with increas-
ing passage numbers [10].
Our results regarding TIMP-1 and TIMP-2 are based only on
the mRNA levels for these inhibitors. Therefore, we cannot
exclude translational modifications of TIMP expression. However,
a number of reports indicate that mRNA and protein levels of
TIMPs in the kidney are tightly coupled. Thus, Jones et al [45]
found increased TIMP-1 mRNA and protein in the kidneys of rats
treated with aminonucleoside. Simulataneous expression of
TIMP-2 mRNA and protein was demonstrated by Carome et al
[46] in glomerulosclerosis. What is more, Tang et al [471 demon-
strated elevated protein and mRNA levels of TIMP- 1 in an
immune-mediated model of interstitial injury.
The intriguing question whether reduced MMP-2 activity does
in fact result in accumulation of extracellular matrix in PKD
remains. While there is no direct experimental evidence presently
available, several observations suggest a close relationship. Ab-
normalities in the turnover of extracellular matrix with accumu-
lation of collagen IV, laminin and fibronectin occur early during
the course of human PKD and in the Han:SPRD rat model [6, 26].
Given the substrate specificity of MMP-2 which primarily de-
grades collagen IV and fibronectin [11], a reduction in the activity
of this proteinase may readily result in accumulation of matrix
components. Therefore, it appears likely that reduced tubular
MMP-2 activity may play a role in the evolution of cystogenesis.
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